Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may guide antiviral treatment duration for respiratory infections

NCT ID NCT06668025

Knowledge-focused Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether measuring a protein called MxA in the blood can help doctors decide when to stop antiviral drugs in patients with flu or COVID-19. Researchers enrolled 86 adults and compared standard care to MxA-guided treatment. The goal was to see if the test could reduce symptom recurrence and shorten hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MxA blood test
What this could lead to
If successful, this could help doctors personalize antiviral treatment duration, potentially reducing unnecessary drug use and hospital stays.
What could go wrong
This is a small pilot study with only 86 participants, so results may not apply broadly. The MxA test may not reliably guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

86 people

The number who actually took part.

Started

Dec 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years old * With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapid antigen test or RT-PCR * Duration of infection ≤14 days for non-severe patients and \< 28 days for patients with severe infections * Currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment Exclusion Criteria: * Current endotracheal intubation and mechanical ventilation * Current vasopressor use * Known immunosuppression * Received interferon therapy within 30 days before screening * Systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery * Received vaccine in the past 30 days * Active tuberculosis * With contraindications for antiviral treatment * Unable to obtain eligible samples * Co-infected with influenza and COVID-19

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 influenza viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza Respiratory viral infections SARS-CoV-2

Contacts and locations

Locations

  • China-Japan Friendship hospital

    Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.